Apyx Medical Corporation (NASDAQ:APYX) Receives $6.67 Average PT from Brokerages

Apyx Medical Corporation (NASDAQ:APYX) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $6.50.

A number of equities analysts have recently issued reports on the company. Craig Hallum raised their price target on Apyx Medical from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, December 29th. Roth Mkm started coverage on shares of Apyx Medical in a research report on Monday, December 15th. They set a “buy” rating and a $6.00 price target for the company. BTIG Research raised shares of Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a report on Wednesday. Finally, Zacks Research raised shares of Apyx Medical to a “hold” rating in a research report on Wednesday, December 17th.

Institutional Trading of Apyx Medical

Several institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC bought a new position in Apyx Medical in the 3rd quarter worth $28,000. Fisher Asset Management LLC purchased a new position in shares of Apyx Medical in the second quarter valued at about $34,000. Caprock Group LLC bought a new position in shares of Apyx Medical in the third quarter worth about $40,000. Osaic Holdings Inc. purchased a new stake in shares of Apyx Medical during the second quarter worth about $50,000. Finally, Franklin Resources Inc. purchased a new stake in shares of Apyx Medical during the third quarter worth about $59,000. 55.33% of the stock is currently owned by institutional investors.

Apyx Medical Price Performance

APYX opened at $3.63 on Wednesday. The company has a current ratio of 5.00, a quick ratio of 3.61 and a debt-to-equity ratio of 2.35. The stock has a market capitalization of $151.84 million, a P/E ratio of -13.44 and a beta of 1.61. The stock has a 50-day moving average price of $3.75 and a 200-day moving average price of $3.33. Apyx Medical has a 12-month low of $0.76 and a 12-month high of $4.50.

Apyx Medical (NASDAQ:APYX) last released its earnings results on Tuesday, March 10th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. Apyx Medical had a negative return on equity of 114.95% and a negative net margin of 21.22%.The company had revenue of $19.16 million during the quarter, compared to the consensus estimate of $19.12 million. Equities analysts predict that Apyx Medical will post -0.68 earnings per share for the current fiscal year.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.